TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01315028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Interpersonal Therapy
Description: Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
Study: NCT01981317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Study: NCT01254461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 100 mg per oral, twice daily for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 4x100 mg per oral, twice daily for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: 40 mg, once daily at Day 1, period A and Day 8, period B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: 40 mg, once daily at Day 1, period A and Day 8, period B
Study: NCT01847365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation
Description: Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
Study: NCT00909363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood drawing in patients with WAS
Description: blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
Study: NCT04527354

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo once a day during 4 weeks
Study: NCT00909363

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: blood drawing in healthy controls
Description: blood will be drawn once in healthy children as controls for platelet parameters
Study: NCT02524288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENG-E2 125 μg/300 μg vaginal ring
Description: Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
Study: NCT02107378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa
Description: DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
Study: NCT01066845

Intervention type: DRUG
Intervention: tadalafil
Description: prescribed in accordance with usual clinical practice
Study: NCT00922363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg Ag85B-ESAT-6 alone
Description: 0.5 mL solution for injection x 2 (2 months interval)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg Ag85B-ESAT-6 + 125/25 µg CAF01
Description: 0,5 mL suspension for injection x 2 (2 months interval)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg Ag85B-ESAT-6 + 313/63 µg CAF01
Description: 0.5 mL suspension for injection x 2 (2 months interval)
Study: NCT02107378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (Paclitaxel or topotecan or doxorubicin)
Description: Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
Study: NCT03498170

Intervention type: DRUG
Group type: OTHER
Intervention: BCT197
Description: Single dose of BCT197

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole 200 mg
Description: Single dose of itraconazole
Study: NCT01278433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOVAX Polio™: Inactivated Poliomyelitis Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01345838

Intervention type: PROCEDURE
Intervention: labrum
Description: Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
Study: NCT00166192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jessner's solution chemical peel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic acid chemical peel
Study: NCT03145246

Intervention type: PROCEDURE
Intervention: regeneration treated teeth loss
Description: number of regeneration treated teeth loss

Intervention type: PROCEDURE
Intervention: regenerated treated teeth with clinical attachment loss
Description: regenerated treated teeth with clinical attachment loss ≥ 2 mm

Intervention type: PROCEDURE
Intervention: regenerated treated teeth with clinical attachment loss
Description: regenerated treated teeth with clinical attachment loss ≥ 2 mm
Study: NCT01555684

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency
Description: percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency
Description: percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
Study: NCT03206736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loop DS surgery
Description: these patients will receive a loop DS bariatric procedure
Study: NCT04224181

Intervention type: RADIATION
Intervention: Cardiac PET
Description: A scan examining blood flow to the heart

Intervention type: RADIATION
Intervention: Cardiac PET
Description: A scan examining blood flow to the heart

Intervention type: RADIATION
Intervention: 99mTc-tilmanocept SPECT/CT
Description: A scan to look at inflammation in the arteries

Intervention type: RADIATION
Intervention: 99mTc-tilmanocept SPECT/CT
Description: A scan to look at inflammation in the arteries

Intervention type: RADIATION
Intervention: Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Description: A scan of the heart and surrounding blood vessels

Intervention type: RADIATION
Intervention: Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Description: A scan of the heart and surrounding blood vessels
Study: NCT03631537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NST group
Description: Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
Study: NCT04982120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repris Needle
Description: Injection of Botox
Study: NCT02504476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 581
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Interaction
Study: NCT01300468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-848125AC
Study: NCT00421343

Intervention type: DRUG
Group type: OTHER
Intervention: alendronate with cholecalciferol
Description: alendronate 70mg /cholecalciferol 2800IU orally once weekly

Intervention type: DRUG
Group type: OTHER
Intervention: calcium carbonate with cholecalciferol
Description: calcium carbonate 500mg /cholecalciferol 200IU orally twice daily

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Falls prevention measures
Description: personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
Study: NCT02551133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 1 hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 1 hour before surgery
Study: NCT04645472

Intervention type: DEVICE
Intervention: CT-Ultrasound
Description: For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
Study: NCT02632708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT01907594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (patch)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy (patch)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cue Exposure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cue Exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Muscle Relaxation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
Study: NCT04229550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Festival participation
Description: One week's participation in Roskilde Festival 2016 or living a normal daily life.
Study: NCT02302794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
Study: NCT02781467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNK-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant Interleukin-2 (rhIL-2)
Study: NCT02538588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer 1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer 2
Study: NCT01926054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar gel
Study: NCT02437097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Gaming
Description: The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and Video Gaming
Description: The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
Study: NCT02469337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate drinks
Description: preoperative carbohydrate drinks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
Study: NCT03936348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise training program with and without FB
Description: Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise training program with and without FB
Description: Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale.
Study: NCT01765686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic Scalpel (Ethicon Endo-Surgery, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure Small Jaw (Covidien, USA)
Study: NCT02491749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra Fast-Track Anesthesia
Description: early extubation at the end or within one hour post operatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra Fast-Track Anesthesia
Description: early extubation at the end or within one hour post operatively
Study: NCT02582437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: History for opioid use
Study: NCT00509639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Metronidazole Ointment
Description: Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
Study: NCT01076556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT05734209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual food
Description: Virtual food eaten using immersive virtual reality equipment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual food
Description: Virtual food eaten using immersive virtual reality equipment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real food
Description: Real food eaten using regular utensils

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real food
Description: Real food eaten using regular utensils
Study: NCT02875041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAGSTIM Rapid2
Study: NCT00487929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal CPAP
Description: Nocturnal

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Nocturnal
Study: NCT01911806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Back care pillow
Description: back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard physical therapy treatment
Description: standard physical therapy treatment are ultrasound therapy and hot pack

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard physical therapy treatment
Description: standard physical therapy treatment are ultrasound therapy and hot pack
Study: NCT00922363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg Ag85B-ESAT-6 + 625/125 µg CAF01
Description: 0.5 mL suspension for injection x 2 (2 months interval)
Study: NCT01621646

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: eggs or egg whites
Description: 2 eggs/day or 4 oz egg whites/day for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eggs or egg whites
Description: 2 eggs/day or 4 oz egg whites/day for 6 months
Study: NCT00855361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
Study: NCT02883517

Intervention type: GENETIC
Intervention: Cytogenetic and molecular studies
Description: Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.